Omeros ROE 2009-2019 | OMER

Current and historical return on equity (ROE) values for Omeros (OMER) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Omeros ROE for the three months ending March 31, 2019 was 0.00%.
Omeros ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2019-03-31 $-0.12B $-0.12B 132.24%
2018-12-31 $-0.13B $-0.10B 185.40%
2018-09-30 $-0.12B $-0.09B 271.19%
2018-06-30 $-0.09B $-0.06B 445.57%
2018-03-31 $-0.07B $-0.03B 348.72%
2017-12-31 $-0.05B $-0.00B 218.56%
2017-09-30 $-0.06B $0.01B 170.99%
2017-06-30 $-0.06B $-0.06B 154.60%
2017-03-31 $-0.06B $-0.05B 157.96%
2016-12-31 $-0.07B $-0.04B 181.33%
2016-09-30 $-0.07B $-0.02B 195.68%
2016-06-30 $-0.07B $-0.05B 236.80%
2016-03-31 $-0.08B $-0.04B 458.82%
2015-12-31 $-0.08B $-0.03B 6080.00%
2015-09-30 $-0.08B $-0.01B 1400.00%
2015-06-30 $-0.08B $0.01B 750.00%
2015-03-31 $-0.08B $0.02B 515.25%
2014-12-31 $-0.07B $-0.04B 389.47%
2014-09-30 $-0.06B $-0.03B 431.37%
2014-06-30 $-0.05B $-0.01B 425.00%
2014-03-31 $-0.05B $0.01B 383.67%
2013-12-31 $-0.04B $-0.02B 228.57%
2013-09-30 $-0.05B $-0.02B 311.86%
2013-06-30 $-0.05B $-0.01B 500.00%
2013-03-31 $-0.04B $-0.02B 355.56%
2012-12-31 $-0.04B $-0.01B 371.43%
2012-09-30 $-0.04B $-0.00B 400.00%
2012-06-30 $-0.04B $-0.02B 388.89%
2012-03-31 $-0.03B $-0.01B 2480.00%
2011-12-31 $-0.03B $-0.01B -504.35%
2011-09-30 $-0.03B $0.00B -212.24%
2011-06-30 $-0.03B $0.01B -158.82%
2011-03-31 $-0.03B $0.02B -136.36%
2010-12-31 $-0.03B $0.02B -109.09%
2010-09-30 $-0.03B $0.02B -87.22%
2010-06-30 $-0.03B $0.03B -104.17%
2010-03-31 $-0.02B $0.04B -139.39%
2009-12-31 $-0.02B $0.04B -289.66%
2009-06-30 $-0.02B $0.00B inf%
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $0.719B $0.030B
Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders.
Stock Name Country Market Cap PE Ratio
Abbott Laboratories (ABT) United States $154.348B 29.07
Medtronic (MDT) Ireland $135.189B 19.31
Stryker (SYK) United States $77.613B 27.70
Boston Scientific (BSX) United States $58.755B 28.17
Baxter (BAX) United States $42.395B 26.72
EssilorLuxottica Societe Anonyme (ESLOY) France $29.186B 0.00
Coloplast (CLPBY) Denmark $25.855B 41.28
Lonza Group Ag (LZAGY) Switzerland $25.565B 0.00
Zimmer Biomet Holdings (ZBH) United States $25.282B 16.24
Terumo (TRUMY) Japan $22.330B 25.68
Smith & Nephew SNATS (SNN) United Kingdom $18.881B 0.00
ResMed (RMD) United States $17.703B 33.82
Sunny Optical Technology (SNPTF) China $12.345B 0.00
Canopy Growth (CGC) Canada $12.272B 0.00
Bio-Rad Laboratories (BIO) United States $9.392B 49.79
William Demant Holdings (WILYY) Denmark $7.263B 0.00
Insulet (PODD) United States $7.231B 526.83
Hill-Rom Holdings (HRC) United States $7.018B 21.28
Perrigo (PRGO) Ireland $7.012B 11.85
Aurora Cannabis (ACB) Canada $6.936B 68.40
GN STORE NORD (GNNDY) Denmark $6.409B 32.73
Haemonetics (HAE) United States $6.251B 51.03
ICU Medical (ICUI) United States $5.188B 30.95
GW Pharmaceuticals (GWPH) United Kingdom $4.991B 0.00
Neogen (NEOG) United States $3.334B 54.21
NuVasive (NUVA) United States $3.016B 24.63
Hutchison China MediTech (HCM) China $2.777B 0.00
Agios Pharmaceuticals (AGIO) United States $2.746B 0.00
National Vision Holdings (EYE) United States $2.480B 52.83
Quidel (QDEL) United States $2.268B 23.54
Aphria (APHA) $1.604B 0.00
Cardiovascular Systems (CSII) United States $1.543B 886.40
Phibro Animal Health (PAHC) United States $1.216B 18.22
AtriCure (ATRC) United States $1.203B 0.00
VAREX IMAGING (VREX) United States $1.174B 24.93
NanoString Technologies (NSTG) United States $1.114B 0.00
Lantheus Holdings (LNTH) United States $1.097B 29.13
PetIQ (PETQ) United States $1.015B 24.66
Quanterix (QTRX) United States $0.779B 0.00
Cerus (CERS) United States $0.761B 0.00
Eagle Pharmaceuticals (EGRX) United States $0.750B 21.04
MacroGenics (MGNX) United States $0.717B 0.00
TG Therapeutics (TGTX) United States $0.681B 0.00
LeMaitre Vascular (LMAT) United States $0.598B 28.97
OraSure Technologies (OSUR) United States $0.530B 24.40
Surmodics (SRDX) United States $0.527B 76.59
Neptune Technologies & Bioresources Inc (NEPT) Canada $0.499B 0.00
Meridian Bioscience (VIVO) United States $0.492B 15.04
BioLife Solutions (BLFS) United States $0.330B 103.12
Utah Medical Products (UTMD) United States $0.321B 22.20
Vapotherm (VAPO) United States $0.320B 0.00
Zynex (ZYXI) United States $0.251B 25.77
Cytosorbents (CTSO) United States $0.242B 0.00
Bovie Medical (APYX) United States $0.214B 0.00
Chimerix (CMRX) United States $0.188B 0.00
Rockwell Medical (RMTI) United States $0.174B 0.00
United Health Products (UEEC) United States $0.170B 0.00
Owens & Minor (OMI) United States $0.166B 3.52
Fonar (FONR) United States $0.142B 7.49
Female Health (VERU) United States $0.134B 0.00
Chembio Diagnostics (CEMI) United States $0.103B 0.00
United-Guardian (UG) United States $0.092B 20.16
InfuSystems Holdings (INFU) United States $0.090B 0.00
Surface Oncology (SURF) United States $0.076B 0.00
Oramed Pharmaceuticals (ORMP) United States $0.067B 0.00
Trinity Biotech (TRIB) Ireland $0.053B 18.33
MRI INTERVENTNS (MRIC) United States $0.052B 0.00